Leiden, The Netherlands, August 20, 2026
VarmX has enrolled the first participant in its global Phase 3 EquilibriX-S trial, marking the start of a pivotal clinical study evaluating VMX-C001 in patients receiving Factor Xa (FXa) inhibitors who require urgent surgery or an invasive procedure. The registrational EquilibriX-S study (NCT07288489) is designed to evaluate whether a single intravenous dose of VMX-C001 can rapidly restore effective blood clotting in patients whose anticoagulation needs to be reversed before urgent surgery. The randomized, controlled trial will recruit participants across more than 20 countries, with clinical efficacy and safety data intended to support potential regulatory submissions worldwide. The study focuses on an important clinical challenge associated with the increasing use of FXa inhibitors: patients receiving these anticoagulants may occasionally require emergency procedures when normal coagulation needs to be restored quickly. For VarmX, the first participant enrollment represents a major transition of VMX-C001 into global registrational Phase 3 development, moving the program toward the pivotal evidence required for potential regulatory approval. The company is developing the candidate as an approach intended to bypass the anticoagulant activity of FXa inhibitors while rapidly restoring the coagulation process during urgent clinical situations.
EquilibriX-S Tests Rapid Hemostatic Restoration
The Phase 3 EquilibriX-S trial will evaluate VMX-C001 against usual pharmacologic care in patients taking FXa inhibitors who require an urgent surgery or procedure. Eligible participants will have received an FXa inhibitor within the previous 15 hours, creating a clinical setting in which rapid restoration of hemostasis may be required. The primary efficacy endpoint is the proportion of participants achieving good or excellent hemostatic efficacy, while safety endpoints will also be assessed throughout the study. The randomized and controlled design is intended to generate robust clinical evidence on whether VMX-C001 can provide reliable coagulation restoration in this high-risk population. The study’s international scope is also significant, with recruitment planned across more than 20 countries to generate data applicable to multiple healthcare systems and regulatory environments. The initiation of enrollment therefore represents more than an early clinical milestone: it begins the pivotal evidence-generation phase for VarmX’s lead program. The central clinical question is whether VMX-C001 can provide rapid and consistent hemostatic control during urgent procedures without introducing an unacceptable safety or thrombotic risk. Results from EquilibriX-S are expected to form a key part of the company’s strategy for potential worldwide regulatory submissions.
VMX-C001 Designed to Bypass FXa Inhibition
VMX-C001 is a recombinant modified human coagulation Factor X protein engineered to be insensitive to Factor Xa inhibitors. The therapeutic concept is designed to bypass the anticoagulant activity of FXa inhibitors and support restoration of the coagulation cascade when urgent hemostasis is required. VarmX is developing VMX-C001 with several potential operational advantages, including rapid fixed-dose intravenous administration regardless of the specific FXa inhibitor being used. The company also states that the approach is designed to preserve the activity of commonly used anticoagulants such as heparin and potentially minimize additional thrombotic risk. These characteristics remain under clinical evaluation and must be confirmed through Phase 3 evidence. The development program is particularly relevant because FXa inhibitors are widely used for chronic anticoagulation, including stroke prevention in atrial fibrillation and prevention of deep vein thrombosis. As their use expands, the clinical need for effective management of anticoagulation during emergency surgery and other urgent interventions also becomes increasingly important. VMX-C001 is therefore being developed around a specific treatment-delivery problem: rapidly restoring coagulation when an FXa-anticoagulated patient cannot wait for the drug effect to wear off naturally. EquilibriX-S will determine whether the candidate’s engineered mechanism can translate into clinically meaningful hemostatic outcomes..
Advertisement
Global Phase 3 Program Advances Toward Registration
The first participant enrollment positions VarmX’s VMX-C001 program for a pivotal stage of development, with the company seeking clinical evidence capable of supporting potential regulatory approval. The program is being advanced with strategic collaboration from CSL, which is supporting the EquilibriX-S trial. VarmX was founded as a spinout from Leiden University Medical Center and has focused its development strategy on approaches designed to bypass the anticoagulant effects of direct oral anticoagulants targeting activated Factor Xa. The company is evaluating VMX-C001 not only for urgent surgery but also for severe spontaneous bleeding associated with FXa inhibitor therapy. For cGxP.wire readers tracking clinical-stage drug development, coagulation therapeutics and global Phase 3 programs, the most important development is the transition of VMX-C001 into a multinational registrational study. The trial’s efficacy and safety results will determine whether the candidate can progress toward regulatory submissions and potentially become a treatment option for patients receiving FXa inhibitors who face urgent surgical intervention. Enrollment of the first participant establishes the clinical-development milestone; the eventual Phase 3 data will determine whether the therapy can deliver the required benefit-risk profile for approval.
Source:VarmX,,press relese
